Lipocine (LPCN) Cash from Operations Growth (1y) (2012 - 2025)
Lipocine (LPCN) Cash from Operations Growth (1y) (2012 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 42.76% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.58% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 151.70% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 172.77% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 56.79% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 100.14% |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -5.39% |
| Jun 30, 2025 | 24.48% |
| Mar 31, 2025 | -181.80% |
| Dec 31, 2024 | 184.16% |
| Sep 30, 2024 | -8.71% |
| Jun 30, 2024 | 24.53% |
| Mar 31, 2024 | 161.29% |
| Dec 31, 2023 | -9.97% |
| Sep 30, 2023 | 18.52% |
| Jun 30, 2023 | -8.64% |
| Mar 31, 2023 | -1.10% |
| Dec 31, 2022 | -120.44% |
| Sep 30, 2022 | 54.19% |
| Jun 30, 2022 | -28.90% |
| Mar 31, 2022 | 4.34% |
| Dec 31, 2021 | 344.15% |
| Sep 30, 2021 | -67.66% |
| Jun 30, 2021 | 42.07% |
| Mar 31, 2021 | -20.30% |
| Dec 31, 2020 | -11.37% |